DAHOS Study: Efficacy of dapagliflozin in treating heart failure with reduced ejection fraction and obstructive sleep apnea syndrome — A 3-month, multicenter, randomized controlled clinical trial
ConclusionsDapagliflozin may be an effective treatment for heart failure complicated with OSA, and could be considered as a potential new treatment for OSA. (Trial registration www.chictr.org.cn, ChiCTR2100049834. Registered 10 August 2021).
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Clinical Trials | Dapagliflozin | Drugs & Pharmacology | Forxiga | Heart | Heart Failure | Obstructive Sleep Apnea | Sleep Apnea | Sleep Disorders | Sleep Medicine | Sodium | Study